רווח למניה בשנים עשר החודשים האחרונים: Denali (DNLI)

Denali Therapeutics (DNLI) is investing billions to overcome the blood-brain barrier, which is temporarily generating losses. The rolling 12-month earnings per share trend on the GURU.Markets chart shows that -1.75 represents the latest metric reading. Strict cold-chain logistics for biomaterials guarantee the stability of results, while operational activities rely on compliance with environmental standards for chemical disposal.

This metric reflects the portion of net income attributable to a single common share, allowing investors to assess the actual efficiency of capital generation over the year. By analyzing the trailing 12-month earnings per share, one can gauge the financial stability of Denali Therapeutics (DNLI), whose profitability depends directly on the optimization of R&D costs and the reliability of external contract manufacturing organizations.